Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting preclinical data regarding its lead compound, buntanetap. According to the announcement, the results show the synergistic effect of buntanetap when combined with the glucagon-like peptide 1 (“GLP-1”) agonist dulaglutide (Trulicity[R]) in a mouse model of Alzheimer’s disease.
Based on data gathered in 2018 showing that buntanetap fully restored memory, learning and synaptic potentiation in an Alzheimer’s mouse model, Annovis recently studied whether buntanetap combined with the GLP-1 agonist dulaglutide produced a synergistic effect in the same animal model. Calling the results “compelling,” the company reported that while buntanetap alone restored cognitive function to 100%, the two compounds together enhanced cognitive function beyond levels seen in healthy controls.
“We are excited to see that buntanetap significantly amplifies the effects of dulaglutide on memory and learning, with a 6- to 10-fold increase in efficacy,” said Annovis Bio founder, president and CEO Maria Maccecchini, PhD, in the press release. “This synergy is particularly important for enhancing treatment outcomes while minimizing potential side effects. As the field of Alzheimer’s research shifts towards combination therapies, we believe our approach holds great promise for offering more effective treatment options for patients.”
To view the full press release, visit https://ibn.fm/jiQu5
About Annovis Bio Inc.
Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information about the company, visit www.AnnovisBio.com.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]
MissionIR is powered by IBN